Daptomycin and Rhabdomyolysis Incidence
Rhabdomyolysis with daptomycin is rare, occurring in approximately 2.7-3.9% of patients, while clinically significant CPK elevations (>5× ULN) occur in 4.9-11.8% of cases.
Incidence Data from Multiple Sources
The FDA label and clinical guidelines establish that myopathy and rhabdomyolysis are recognized complications of daptomycin therapy 1. The most recent real-world data provides the clearest picture:
- Rhabdomyolysis: 2.7% in a large multicenter French study of 1,407 patients 2 and 3.9% in an OPAT cohort 3
- Significant CPK elevation (>500 U/L): 11.8% 3
- Muscle toxicity (CPK >5× ULN and/or rhabdomyolysis): 4.9% 2
These rates are consistent with the IDSA guidelines noting that CPK elevations "rarely treatment limiting" occurred in patients receiving 6 mg/kg/day 4.
Critical Risk Factors
The evidence identifies specific high-risk populations requiring heightened vigilance:
Independent Risk Factors for Muscle Toxicity:
- Concomitant myotoxic medications (statins, fibrates): OR 6.68 (95% CI 3.28-13.97) 2
- Male sex: OR 4.2 (95% CI 1.05-16.61) 3
- Obesity: OR 2.25 (95% CI 1.07-4.72) 2
- Cerebrovascular disease: OR 11 (95% CI 1.21-99.86) 3
Statin Co-Administration:
Meta-analysis demonstrates significantly increased risk when daptomycin is combined with statins:
- CPK elevation ≥ULN: OR 2.55 (95% CI 1.78-3.64) 5
- CPK elevation ≥5× ULN: OR 1.89 (95% CI 1.06-3.35) 5
- Rhabdomyolysis: OR 11.60 (95% CI 1.81-74.37) 5
Despite this, one retrospective study found no myopathy in 52 patients receiving concurrent statin-daptomycin therapy 6, though this conflicts with the larger meta-analysis and should be interpreted cautiously.
Timing and Monitoring
CPK elevation typically occurs within 9-16 days of therapy initiation 3, though cases have been reported earlier 7. The FDA label explicitly states that CPK elevations were more frequent with doses >6 mg/kg/day 1.
Mandatory Monitoring Protocol (per FDA):
- Weekly CPK monitoring for all patients 1
- More frequent monitoring (>weekly) for:
- Patients with renal impairment
- Concurrent HMG-CoA reductase inhibitor use
- Any CPK elevation during treatment 1
- Monitor for muscle pain/weakness, particularly in distal extremities 1
Discontinuation Thresholds (per FDA):
- Discontinue immediately if unexplained myopathy symptoms with CPK >1,000 U/L (~5× ULN) 1
- Discontinue immediately if asymptomatic but CPK >2,000 U/L (≥10× ULN) 1
- Consider suspending statins temporarily in patients receiving daptomycin 1
Real-World Practice Gap
A critical finding from recent data: only 34.2% of patients received documented CPK monitoring despite guideline recommendations 2. Additionally, statins were continued without discontinuation in 15.6% of cases where co-prescribed 2. This represents a significant safety concern given the 11-fold increased risk of rhabdomyolysis with concurrent use.
Special Populations
High-dose daptomycin (≥7.5 mg/kg) in patients with severe renal dysfunction (CrCl <30 mL/min) showed only 1 case of rhabdomyolysis in 50 patients, suggesting the risk may not be substantially higher in ESRD when appropriately monitored 8. However, the FDA mandates more frequent monitoring in this population 1.
Clinical Implications
The incidence of rhabdomyolysis is low but not negligible, particularly with:
- Doses >6 mg/kg/day (now standard practice at 8-12 mg/kg for bacteremia 9)
- Prolonged therapy (median 27-37 days in OPAT settings 3, 8)
- Concurrent myotoxic medications
The combination of inadequate monitoring (66% not monitored) and continued statin use (15.6%) in real-world practice represents a modifiable risk that could reduce the already low incidence further 2.